A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Excessive Daytime Sleepiness

In brief

Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.

Key facts

Study ID

NCT07082829

Run by

Centessa Pharmaceuticals (UK) Limited

People needed

208

Starts

2025-06-30

Expected to finish

2026-06-15

Last updated by the study team

2025-12-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• Site #1 — Lincoln, Nebraska, United States (enrolling)
• Site #2 — Eatontown, New Jersey, United States (enrolling)
• Site #3 — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.